The biopharmaceutical company based in Kuopio, Finland knows that innovations do not appear out of thin air.
FinVector has worked hard for internationalization. The working language is English, and about a fifth of the employees have been recruited from outside Finland. The company collaborates with educational institutions, such as the University of Eastern Finland, and employs international students from many fields.
Finvector has attracted experts from all over the world, from biomedical experts to members of the management team.
“Finland alone can’t satisfy our need for specialized knowledge. Without international recruitment, we should train experts ourselves. That would be a long journey,” says HR Director Tiina Bies.
FinVector has grown rapidly thanks to its unique gene therapy drug for the treatment of non-muscle invasive bladder cancer.
“This is a breakthrough and a success story, not only for Kuopio and Finland, but for the whole world. If standard treatment is unsuccessful, bladder removal has been the usual treatment. Everyone can imagine how this may affect the quality of life,” Bies says.
In December 2022, the targeted therapy received the U.S. Food and Drug Administration’s (FDA) marketing approval. This marked the beginning of Finvector’s transition from a product development company into a commercial pharmaceutical company – and created a great need for additional recruitment.